Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn Sigmund-Freud-Str. 25 D-53105 Bonn Tel: 0228-287-15750
vorherige Seite | nächste Seite | Telefonlisten | Stationäre Aufnahme | Suchen | Impressum

Neurooncology

Key Publications

Glas M, Coch C, Trageser D, Daßler J, Simon M, Koch P, Mertens J, Quandel T, Gorris R, Reinartz R, Wieland A, von Lehe M, Pusch A, Roy K, Schlee M, Neumann H, Fimmers R, Herrlinger U, Brüstle O, Hartmann G, Besch R, Scheffler B. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells; accepted for publication.

Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M. Vemurafenib for leptomeningeal melanomatosis: activity beyond the barrier. J Clin Oncol; accepted for publication.

Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U. Group Of The German Cancer Society FT. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011;70:445-453.

Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M, Schildhaus HU, Garbe S, Steinfarz B, Pietsch T, Steindler DA, Schramm J, Herrlinger U, Brüstle O, Scheffler B. Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol. 68:264-269, 2010

Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U.Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 67:182-189, 2010

Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U.Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 97:389-392, 2010

Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U.Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27:1257-1261, 2009

Glas M, Hundsberger T, Stuplich M, Koch D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U.Nimustine plus teniposide in recurrent glioblastoma, Oncology 76:184-189, 2009

Kurzwelly D, Müller CA, Korfel A, Thiel E, Linnebank M, Weller M, Herrlinger U.Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients. J Neurooncol 90:53-55, 2008

Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M.UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 24:4412-4417, 2006